Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
144,65 €
-10,02 %
Neurocrine Biosciences (NBIX) had its price target raised by Guggenheim from $200.00 to $222.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Cantor Fitzgerald from $210.00 to $215.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Piper Sandler from $207.00 to $210.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by TD Cowen from $200.00 to $220.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Royal Bank Of Canada from $195.00 to $198.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $246.00 to $249.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Neurocrine Bioscience diskutieren